Table 3.
Antiretroviral drug and haematological characteristics of HIV-infected patients on first-line HAART at Kombolcha town health facilities, 2019
| Variables | Case, n (%) | Control, n (%) |
| Original ART regimen | ||
| D4T-based | 47 (36.2) | 76 (29.3) |
| ZDV-based | 40 (30.8) | 53 (20.5) |
| TDF-based | 43 (33.1) | 130 (50.2) |
| Change of ART | ||
| Yes | 57 (43.8) | 94 (36.3) |
| No | 73 (56.2) | 165 (63.7) |
| Number of changes in ART | ||
| Once | 50 (87.7) | 84 (89.4) |
| Twice or more | 7 (12.3) | 10 (10.6) |
| Current ART regimen at the time of the VL test | ||
| ZDV-based | 62 (47.7) | 71 (27.4) |
| TDF-based | 68 (52.3) | 188 (72.6) |
| Frequency of treatment | ||
| Once a day | 41 (31.5) | 128 (49.4) |
| Twice a day | 89 (68.5) | 131 (50.6) |
| Number of ART pills | ||
| One pill per day | 40 (30.8) | 128 (49.4) |
| Two pills per day | 45 (34.6) | 51 (19.7) |
| Three pills per day | 45 (34.6) | 80 (30.9) |
| Adherence | ||
| Good | 105 (80.8) | 231 (89.2) |
| Poor | 25 (19.2) | 28 (10.8) |
| Duration on ART | ||
| 6–23 months | 9 (6.9) | 13 (5) |
| 24–47 months | 22 (16.9) | 45 (17.4) |
| ≥48 months | 99 (76.2) | 201 (77.6) |
| Current CPT use during VL test | ||
| Yes | 41 (31.5) | 58 (22.4) |
| No | 89 (68.5) | 201 (77.6) |
| Baseline CD4 count | ||
| ≤250 cells/mm3 | 94 (72.3) | 150 (57.9) |
| >250 cells/mm3 | 36 (27.7) | 109 (42.1) |
| Recent CD4 count | ||
| ≤250 cells/mm3 | 66 (50.8) | 55 (21.2) |
| >250 cells/mm3 | 64 (49.2) | 204 (78.8) |
| Baseline Hgb | ||
| <12 g/dL | 58 (44.6) | 74 (28.6) |
| ≥12 g/dL | 72 (55.4) | 185 (71.4) |
| Recent Hgb | ||
| <12 g/dL | 40 (30.8) | 45 (17.4) |
| ≥12 g/dL | 90 (69.2) | 214 (82.6) |
ART, antiretroviral therapy; CPT, cotrimoxazole preventive therapy; D4T, Stavudine; HAART, highly active antiretroviral therapy; Hgb, haemoglobin; TDF, tenofovir; ZDV, Zidovudine.